NYXOAH SA
NYXHNASDAQTrading Snapshot
- Day Range
- $1.58 – $1.61
- 52-Week Range
- —
- Volume
- $3.26B
- Avg Volume
- $3.31B
- Shares Outstanding
- 100.1M
- Next Earnings
- Sep 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $8M
- P/E Ratio
- —
- P/S Ratio
- 9.5x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own NYXH
- ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NYXOAH SA
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $6
Piper Sandler analyst Adam Maeder reiterates Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $7 to $6.
Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript
Nyxoah SA (NYXH) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsPearson Dennis - Investor Relations AssociateOlivier Taelman - CEO...
Nyxoah Lowers FY2026 Sales Guidance from $42.156M-$46.840M to $41.852M-$46.502M vs $44.410M Est
Nyxoah (NASDAQ:NYXH) lowers FY2026 sales outlook from $42.156 million-$46.840 million to $41.852 million-$46.502 million vs $44.410 million estimate.
Nyxoah Q2 EPS $(0.67) Misses $(0.47) Estimate, Sales $8.922M Miss $9.030M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.47) by 42.55 percent. This is a 8.06 percent decrease over losses of $(0.62) per share from the same